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Abstract
Background: Intrapartum and neonatal single-dose nevirapine (NVP) reduces the risk of mother-to-child HIV transmission
but also induces viral resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs. This drug resistance largely
fades over time. We hypothesized that women with a prior single-dose NVP exposure would have no more than a 10%
higher cumulative prevalence of failure of their NNRTI-containing antiretroviral therapy (ART) over the first 48 wk of therapy
than would women without a prior exposure.
Methods and Findings: We enrolled 355 NVP-exposed and 523 NVP-unexposed women at two sites in Zambia, one site in
Kenya, and two sites in Thailand into a prospective, non-inferiority cohort study and followed them for 48 wk on ART. Those
who died, discontinued NNRTI-containing ART, or had a plasma viral load $400 copies/ml at either the 24 wk or 48 wk
study visits and confirmed on repeat testing were characterized as having failed therapy. Overall, 114 of 355 NVP-exposed
women (32.1%) and 132 of 523 NVP-unexposed women (25.2%) met criteria for treatment failure. The difference in failure
rates between the exposure groups was 6.9% (95% confidence interval [CI] 0.8%–13.0%). The failure rates of women
stratified by our predefined exposure interval categories were as follows: 47 of 116 women in whom less than 6 mo elapsed
between exposure and starting ART failed therapy (40%; p,0.001 compared to unexposed women); 25 of 67 women in
whom 7–12 mo elapsed between exposure and starting ART failed therapy (37%; p=0.04 compared to unexposed women);
and 42 of 172 women in whom more than 12 mo elapsed between exposure and starting ART failed therapy (24%; p=0.82
compared to unexposed women). Locally weighted regression analysis also indicated a clear inverse relationship between
virologic failure and the exposure interval.
Conclusions: Prior exposure to single-dose NVP was associated with an increased risk of treatment failure; however, this risk
seems largely confined to women with a more recent exposure. Women requiring ART within 12 mo of NVP exposure
should not be prescribed an NNRTI-containing regimen as first-line therapy.
Please see later in the article for the Editors’ Summary.
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In many parts of the world, pediatric AIDS remains an
uncontrolled epidemic [1]. The vast majority of children who
become HIV infected acquire the virus from their mothers, either
during pregnancy or delivery, or afterward, while breast-feeding
[2]. Intrapartum and neonatal single-dose nevirapine (NVP) can
reduce the risk of perinatal HIV transmission by nearly half [3].
This efficacy is maintained even in the face of breast-feeding [4]
and can be enhanced through the addition of antenatal zidovudine
(ZDV) [5] or combination ZDV/lamivudine (3TC) [6]. The
operational simplicity of single-dose NVP has made it the
cornerstone intervention for prevention of mother-to-child HIV
transmission (PMTCT) worldwide [7-10], yet its convenience may
come at an unintended cost. One-third or more of women who are
exposed to the drug—either alone or as a component of a non-
suppressive prophylactic regimen—will develop high-level resis-
tance to the non-nucleoside reverse transcriptase inhibitor
(NNRTI) class of antiretroviral drugs [11,12]. Population
genotyping methods indicate that these drug resistance mutations
(which peak in prevalence within 8 wk of exposure) gradually fade
over a period of 6 to 12 months [13,14]. However, results from
more sensitive assays suggest that drug resistance mutations may
persist indefinitely in minority virus populations [15]. The clinical
implications of this resistance for women who eventually need
antiretroviral therapy (ART) for their own health are not
completely understood, but are concerning [16,17], given the
worldwide predominance of NNRTI-containing regimens for first-
line ART.
We sought to evaluate the effectiveness of NNRTI-based ART
in women who were previously exposed to a single, intrapartum
dose of NVP. We were particularly interested in the effect of the
interval between NVP exposure and ART inception, and whether
there was any clear temporal threshold for increased risk of
virologic failure.
Methods
Study Population
The NNRTI Response Study enrolled single-dose NVP-
exposed and -unexposed women starting ART at two sites in
Lusaka, Zambia (Kanyama Health Centre and Matero Reference
Centre), one site in Nairobi, Kenya (Kenyatta National Hospital),
and two sites in Bangkok, Thailand (Siriraj and Rajavithi
Hospitals). Study patients were treated according to national
protocols operant in each country. All participating sites were
public-sector outpatient clinics with ongoing, free ART services
available. Women who were at least 18 y of age and who met local
criteria to start ART were eligible to participate. In Kenya and
Zambia, women who met any of the following criteria were
eligible: (1) CD4
+ cell count ,200/ml; (2) World Health
Organization (WHO) clinical stage IV; or (3) WHO stage III
and CD4
+ cell count ,350/ml. In Thailand, women whose CD4
+
cell count was ,200/ml or who had clinical AIDS were eligible. In
all countries, we excluded from the study women who were
currently pregnant, those with any prior exposure to ART (other
than single-dose NVP and/or ZDV monotherapy for PMTCT),
and those who were not starting an NNRTI-based first-line
therapy.
We determined NVP exposure through a structured procedure
that considered the dates of a prospective enrollee’s last pregnancy
in relation to available PMTCT services at the delivery site and
reviewed her prior labor and delivery records, if available. We also
accepted verbal confirmation of prior single-dose NVP ingestion,
provided the woman was able to identify a NVP tablet from a
photograph. In cases where NVP exposure status was uncertain,
we did not offer entry into the study.
The date of exposure was taken as the date of delivery. In the
few women who reported more than one prior exposure to single-
dose NVP, we took the date of the most recent exposure. During
protocol planning, we noted that NVP-unexposed women
available for study recruitment comprised mostly self-referrals of
women with symptomatic HIV disease; they were thus generally
more ill upon presentation than NVP-exposed women, who
tended to be referred from postnatal care. In an effort to mitigate
the effect of confounding by disease status on our study outcomes,
we frequency-matched NVP-exposed and unexposed women by
both CD4
+ cell count and WHO stage at entry. Our matching
scheme used a 363 table that included three CD4
+ strata
(0–49 cells/ml, 50–200 cells/ml, and .200 cells/ml) and three
WHO stage strata (WHO stage I/II, III, and IV). We originally
planned to enroll equal numbers of NVP-exposed and -unexposed
women in each cell of this 363 table; however, in June 2006, in
response to a slower than expected rate of enrollment among
NVP-exposed women, we increased the enrollment of unexposed
to exposed women to a 3:2 ratio.
Clinical Care and Study Procedures
In each of the three countries, most clinical care was delivered by
non-physician clinicians (i.e., nurses and/or clinical officers), with
rotating study physicians providing oversight. The study did not
direct individual treatment decisions, but rather relied upon local
guidelines and clinician discretion to manage patients. We
attempted to evaluate all NVP-exposed women for study enroll-
ment. Because unexposed women weremuch morenumerous,each
site enrolled only a subset of these unexposed women, according to
availability of open cells within our disease-status matching scheme.
At study enrollment, study clinicians conducted a history and
physical examination, a clinical evaluation for tuberculosis (TB) co-
infection, and additional laboratory tests including hemoglobin
concentration and plasma viral load. Each site quantified HIV-1
RNA in venous plasma using a commercially available polymerase
chain reaction assay. The Siriraj Hospital in Bangkok used the
COBAS TaqMan HIV-1 Test; all other sites used the Roche
Amplicor HIV-1 Monitor v. 1.5 (both from Roche Molecular
Systems, Pleasanton, CA, USA).
First-line ART drug regimens were started within 2 wk of study
enrollment and included two nucleoside reverse transcriptase
inhibitors (3TC, plus either stavudine [d4T] or ZDV), and one
NNRTI (either NVP or efavirenz [EFV]) [18]. In Kenya and
Zambia, we used only proprietary drug formulations; in Thailand,
we used a locally produced fixed-dose combination of d4T/3TC/
NVP for most women (GPO-VIR). In Kenya and Thailand, all
patients except one started a d4T-containing regimen, whereas in
Zambia patients started either ZDV or d4T according to drug
availability (ZDV was avoided in patients whose baseline hemoglo-
bin was ,10 g/dl). To avoid a drug interaction between NVP and
rifampin, clinicians generally deferred ART (and study enrollment)
for patients receiving acute phase therapy for tuberculosis, unless
their CD4
+ lymphocyte count was,50 cells/ml, in whichcase ART
was started immediately with an EFV-based regimen. Each site
prescribed co-trimoxazole prophylaxis against Pneumocystis pneu-
monia to women who met WHO criteria for its use [19].
Study visits occurred once prior to starting ART, once on or
around the day of ART commencement, then at weeks 2, 4, 8, 16,
24, 36, and 48 on ART. Routine clinical and pharmacy visits
occurred according to local guidelines and varied only slightly.
The Zambian and Kenyan sites dispensed antiretroviral drugs in
ART after One Intrapartum Dose of Nevirapine
PLoS Medicine | www.plosmedicine.org 2 February 2010 | Volume 7 | Issue 2 | e1000233monthly increments, whereas the Thai sites dispensed according to
the same schedule as study visits.
We repeated the CD4
+ cell count and plasma viral load tests at
24 and 48 wk. Women who had $400 copies of viral RNA/ml
plasma at either of these scheduled visits were evaluated for
medication adherence and scheduled for a repeat viral load 1 mo
later. Those who had persistent viremia were categorized as
virologic failures and the clinicians caring for them had the option
of switching to second-line therapy with a ritonavir-boosted
protease inhibitor or continuing NNRTI-based ART. The study
protocol did not direct individual treatment decisions, but, in
general, clinician discretion in the management of low-level
viremia (e.g., ,1,000 copies/ml) was such that, in some cases,
women who were clinically and immunologically well were
managed expectantly and not immediately switched to second-
line therapy. Those who had ,400 copies of viral RNA/ml
plasma on repeat measurement were considered responders, and a
third repeat measurement not routinely performed.
Patients on ART presented at scheduled intervals to the clinic to
collect their antiretroviral drugs. Each dispensation included a
2- or 3-d buffer of extra pills, and we allowed pre-registered
treatment partners to collect a patient’s medication. Missed visits
were followed up by home visits and/or telephone calls. Nurses or
pharmacy technicians performed adherence counseling. We
assessed adherence by the participants’ report of the number of
doses missed in the 7 d before each scheduled visit, and a priori,
chose to dichotomize self-reported adherence as $95% or ,95%.
Study Design and Definition of Failure
The NNRTI Response Study was designed as a prospective,
observational, non-inferiority study [20]. The primary study
hypothesis was that women who had previously received single-
dose NVP for PMTCT would have a failure rate on NNRTI-based
ART that was not more than 10% greater than that observed for
women without a prior exposure (i.e., a non-inferiority margin of
10%). Under this non-inferiority design, the failure rate for the
NVP-exposed group would be considered equivalent to that of the
NVP-unexposed group if the upper bound of the 95% confidence
interval (CI) for the difference between groups did not exceed 10%.
The study was also designed to compare the failure rate among
unexposed women to that of (a) women exposed to NVP within
6 mo of starting ART, (b) women exposed 7–12 mo before starting
ART, and (c) women exposed .12 mo prior to starting ART. The
primary study outcome was assessed at 48 wk after initiating ART.
For the primary analysis, a participant was considered as having
failed at 48 wk if she died prior to that time, was no longer receiving
NNRTI-based ART for any reason, or had a plasma viral load
$400 copies/ml (confirmed with repeat testing) at either the 24 or
48 wk study visits.
We also conducted two planned secondary analyses of
treatment failure, namely (a) one that excluded women who died
within 90 d of starting therapy, and (b) an ‘‘on-treatment’’ analysis
that excluded women who died, were lost to follow-up, or switched
to second-line therapy for reasons of toxicity. In contrast to the
primary analysis, the on-treatment analysis did not categorize as
failures those women whose viral load was $400 copies/ml at
24 wk who subsequently went on to achieve suppression at 48 wk,
unless they were switched to a second-line therapy by their
clinician in response to the 24 wk viral load measurement.
For the sample size calculation for the primary analysis, we
assumed a 20% failure rate in the NVP-unexposed group and
chose a non-inferiority margin of 10%. Thus, if the failure rate in
the exposed group was ,30%, we would consider that rate non-
inferior. We assumed a failure rate of 20% in the NVP-exposed
group and a 15% drop-out rate. Under these assumptions we
would need 235 women in each group to have 80% power, or 350
women in each group (700 total) to have 90% power, to establish
non-inferiority using an asymptotic normal test of difference to
compare two independent binomial proportions at the one-sided
alpha=0.05 significance level. As the difference between the two
failure rates increases, however, the sample size required to
establish non-inferiority also increases.
Statistical Analyses
We present standard summary statistics of the enrollment or
baseline data, including counts, proportions, medians, and
interquartile ranges (IQRs). When appropriate, variables were
categorized using standard or clinically relevant cut-points.
Nonparametric Wilcoxon rank-sum tests and Kruskall-Wallace
tests were used to compare the medians of selected baseline
variables between countries and between NVP-exposed and
unexposed women. We generated a histogram to illustrate the
distribution of the intervals between single-dose NVP exposure
and ART commencement (the ‘‘exposure interval’’). We calculat-
ed exact binomial confidence intervals around the proportion of
treatment failures for NVP unexposed women and for each of the
three exposure interval categories and used Fisher’s exact test to
compare these proportions. We used exact logistic regression to
estimate the odds of treatment failure as a function of individual
baseline variables. For the multiple logistic regression analyses, we
included in all models a common set of baseline predictor variables
(exposure interval, country, CD4
+ count, viral load, WHO stage,
and age). We also included hemoglobin and body mass index in
particular models when they were significant at the p,0.05 level
(Wald Chi-square test). We then performed multiple logistic
regression to model the odds of treatment failure as a function of
selected baseline variables and to estimate adjusted odds ratios
(ORs) with Wald confidence intervals [21]. Furthermore, we
performed locally weighted regression (using the LOESS proce-
dure in SAS software) to model nonparametrically the risk of
treatment failure as a function of the exposure interval for the
primary and on-treatment analyses [22]. All of these statistical
calculations were performed using SAS software, version 9.1.3
(SAS Institute, Cary, North Carolina).
Study Monitoring
The study protocol and its informed consent procedures were
approved before study initiation by the Institutional Review
Boards at the Thai Ministry of Public Health, the Mahidol
University - Siriraj Hospital, the University of Zambia School of
Medicine, the Kenyatta National Hospital (Kenya), University of
Alabama at Birmingham and US Centers for Disease Control and
Prevention (CDC). All participants provided written informed
consent. A Data Monitoring Committee with representatives from
each country and from CDC, who were not involved in the study,
met periodically to review study progress and interim analyses.
Enrollment began on 9 June 2005 in Zambia, on 15 August 2005
in Thailand, and on 9 June 2006 in Kenya. We completed
enrollment at all sites the week of 22 January 2007. All women
were followed for 48 wk.
Results
Cohort Description
We enrolled 878 women, 509 (58%) from Zambia, 152 (17%)
from Kenya, and 217 (25%) from Thailand (Table 1). Compared
to Zambian women, Kenyan women weighed more (median 55
versus 52 kg, p,0.05; Wilcoxon rank-sum test) and had lower
ART after One Intrapartum Dose of Nevirapine
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p,0.05), while Thai women had higher body-mass index (median
21.1 versus 19.7 kg/m
2) and higher hemoglobin concentrations
(median 11.4 versus 10.8 g/dl, p,0.05). A total of 355 women
(40%) were NVP-exposed and 523 (60%) were NVP-unexposed
(Table 2). NVP-exposed women were younger (29 versus 33
median y, p,0.05), had higher median CD4
+ counts (160 versus
139 cells/ml; p,0.05), and had lower median plasma viral loads at
baseline (5.0 versus 5.2 log copies/ml, p,0.05). The median time
between NVP ingestion and starting ART among the 355 exposed
women was 11.8 mo (IQR 4.4–24.7) and differed by country: in
Kenya, the median interval was 3.9 mo (IQR 1.8–7.2), in Zambia
it was 12.0 mo (IQR 5.7–23.1), and in Thailand it was 24.2 mo
(IQR 12.3–45.9; p,0.05; Kruskall-Wallace test; Figure 1). All
women in Kenya and Zambia received single-dose NVP only. All
women in Thailand received short-course ZDV in addition to
single-dose NVP for PMTCT. No women received an antiretro-
viral therapy ‘‘tail’’ in order to limit emergence of NVP resistance
after delivery, because that practice had not been implemented as
standard of care in any of these countries at the time of single-dose
NVP exposure by these women.
Patient Status at 48 Weeks of Follow-Up
Between enrollment and 48 wk of follow-up, 58 women (6.6%)
died, including 38 (4.3%) before 90 d on therapy (Figure 2). Fifty-
seven of 58 deaths involved circumstances that were probably or
possibly related to HIV disease, and one death was attributed to a
road traffic accident. An additional 53 women (6.0%) were lost to
follow-up or voluntarily withdrew from the study. Forty-three
women (4.9%) were switched by their provider to a non-NNRTI-
based antiretroviral regimen: 29 women (3.3%) were switched
after a 24-wk viral load measurement indicated virologic failure,
12 women (1.4%) were switched for reasons of toxicity before 24
wk, and two women (,1%) were switched for reasons of toxicity
between 25 and 48 wk. In total, 724 women (82%) completed
48 wk of follow-up on an NNRTI-containing regimen.
NVP-exposedwomenweremorelikelytomeetthestudy’sprimary
criteria for failure at 48 wk than were NVP-unexposed women
Table 1. Baseline characteristics of participants enrolled in the NNRTI Response Study—Zambia, Kenya, Thailand (2005–2008).
Characteristics Zambia (n=509) Kenya (n=152) Thailand (n=217)
n (%) Median (IQR) n (%) Median (IQR) n (%) Median (IQR)
Age, y 32 (28–36) 32 (28–36) 32 (28–37)
,30 189 (37) 54 (36) 75 (35)
Weight, kg 52 (46–57) 55 (47.8–60.8)* 50 (45–56)
,50 195 (38) 46 (30) 104 (48)
Body mass index, kg/m
2 19.7 (18.3–21.9) 19.9 (17.7–22.6) 21.1 (18.8–23.2)*
,18 113 (22) 49 (32) 38 (18)
WHO stage
I or II 215 (42) 61 (40) 140 (64)
III 254 (50) 70 (46) 34 (16)
IV 40 (8) 21 (14) 43 (20)
CD4
+ lymphocyte count, cells/ml 148 (88–211) 147 (76.5–212.5) 148 (50–220)
0 to 49 63 (12) 27 (18) 54 (25)
50 to 199 304 (60) 80 (53) 95 (44)
$200 142 (28) 45 (30) 68 (31)
Plasma viral load, log copies/ml ([missing=6) 5.0 (4.4–5.4) 5.3 (4.8–5.9) 5.0 (4.6–5.5)
,4.0 74 (15) 15 (10) 25 (12)
4.0 to ,5.0 186 (37) 31 (20) 79 (36)
$5.0 243 (48) 106 (70) 113 (52)
Hemoglobin, g/dl (missing=16) 10.8 (9.6–12.0) 10.4 (8.8–12.0)* 11.4 (10.4–12.3)*
,8.0 33 (7) 15 (10) 6 (3)
NNRTI initially prescribed
NVP 497 (98) 131 (86) 192 (88)
EFV 12 (2) 21 (14) 25 (12)
TB at baseline 44 (9) 12 (8) 15 (7)
Interval between nevirapine exposure and starting
NNRTI-based ART (exposed women only), mo
N=201 12.0 (5.7–23.1) N=67 3.9 (1.8–7.2)* N=87 24.2 (12.3–45.9)*
Unexposed 308 (61) 85 (56) 130 (60)
1–6 54 (11) 46 (30) 16 (7)
7–12 46 (9) 16 (11) 5 (2)
.12 101 (20) 5 (3) 66 (30)
*p-Value,0.05, compared to Zambia by Wilcoxon rank-sum test.
doi:10.1371/journal.pmed.1000233.t001
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[25.2%; 95% CI 21.6%–29.2%]). The difference in failure rates
between the NVP-exposed and unexposed groups was6.9%(95% CI
0.8%–13.0%). The upper bound of this 95% CI exceeds our
predefined 10% non-inferiority margin (i.e., we failed to confirm non-
inferiority). The treatment failure rates of women stratified by
exposure interval were as follows:47 of116 women inwhomless than
6 mo elapsed between exposure and starting ART failed therapy
(41%; 95% CI32%–50%; p=0.001 compared tounexposed women,
Fisher’s exact test); 25 of 67 women in whom 7–12 mo elapsed
between exposure and starting ART failed therapy (37%; 95% CI
26%–50%; p=0.04 compared to unexposed women, Fisher’s exact
test); and 42 of 172 women in whom more than 12 mo elapsed
between exposure and starting ART experienced treatment failure
(24%; 95% CI 18%–32%; p=0.92 compared to unexposed women,
Fisher’s exact test). This relationship was also evident in locally
weighted regression analysis, which suggests the increased risk of
treatment failure may extend to women in whom as many as 15 mo
have elapsed between NVP ingestion and starting ART (Figure 3).
Factors Associated with Treatment Failure at 48 Weeks in
the Primary Analysis
In both crude and adjusted analysis, women who had an
interval of less than 6 mo between exposure to NVP and starting
ART were more likely to experience treatment failure than women
without exposure (adjusted OR 2.16; 95% CI 1.34–3.49; Table 3).
Women whose exposure interval was between 7 and 12 mo had an
increased risk of treatment failure that was not statistically
significant (adjusted OR 1.47; 95% CI 0.82–2.65), whereas
women whose exposure interval was more than 12 mo had no
evidence of increased risk (adjusted OR 1.02; 95% CI 0.66–1.59).
Also associated with failure in crude and adjusted analyses were
enrollment at a Kenyan or Zambian site, baseline CD4
+ count 0–
49 cells/ml, plasma viral load $5.0 log copies/ml, WHO stage III
or IV disease, age ,30 y, hemoglobin ,8.0 g/dl, and body mass
index ,18 kg/m
2 (Table 3). Thirty-eight women died before
completing 90 d of ART, including 23 (4.4%) of 523 unexposed
women and 15 (4.2%) of 355 NVP-exposed women (p=0.9,
Fisher’s exact test). Excluding these early deaths from the primary
analysis did not appreciably change the findings (Table 4).
Factors Associated with Virologic Failure in the On-
Treatment Analysis
At 24 wk of follow-up 41 (9%) of 462 unexposed women and 46
(14%) of 320 NVP-exposed women had a plasma viral load
$400 copies/ml. Of these 87 women with detectable virus at
24 wk, 31 were changed to a protease inhibitor-based regimen and
56 continued their NNRTI-based therapy. Of 56 whose NNRTI-
Table 2. Baseline characteristics of participants enrolled by prior exposure to single-dose nevirapine in the NNRTI Response
Study—Zambia, Kenya, Thailand (2005–2008).
Characteristics
Unexposed to Single-Dose
Nevirapine (N=523)
Exposed to Single-Dose
Nevirapine (N=355) Total
n (%) Median (IQR) n (%) Median (IQR) n (%) Median (IQR)
Age, y 33 (29–39) 29 (26–33)* 32 (28–36)
,30 136 (26) 182 (51) 318 (36)
Weight, kg 52 (47–58) 51 (45–58) 52 (46–58)
,50 200 (38) 145 (41) 345 (39)
Body mass index, kg/m
2 20.2 (18.4–22.6) 19.7 (18.0–22.3) 20.0 (18.3–22.5)
,18 111 (21) 89 (25) 200 (23)
WHO stage
I or II 236 (45) 180 (51) 416 (47)
III 219 (42) 139 (39) 358 (41)
IV 68 (13) 36 (10) 104 (12)
CD4+ lymphocyte count, cells/ml 139 (71–209) 160 (90–219)* 147.5 (77–215)
0 to 49 98 (19) 46 (13) 144 (16)
50 to 199 280 (54) 199 (56) 479 (55)
$200 145 (28) 110 (31) 255 (29)
Plasma viral load, log copies/ml [missing=6] 5.2 (4.6–5.6) 5.0 (4.3–5.4)* 5.1 (4.5–5.5)
,4.0 52 (10) 62 (17) 114 (13)
4.0 to ,5.0 179 (34) 117 (33) 296 (34)
$5.0 288 (55) 174 (49) 462 (53)
Hemoglobin, g/dl (missing=16) 10.8 (9.5–12.0) 11.0 (9.8–12.2) 10.9 (9.6–12.1)
,8.0 31 (6) 23 (7) 54 (6)
NNRTI initially prescribed
NVP 481 (91) 339 (95) 820 (93)
EFV 42 (8) 16 (5) 58 (7)
TB at baseline 53 (10) 18 (5) 71 (8)
*p-Value,0.05, compared to unexposed by Wilcoxon rank-sum test.
doi:10.1371/journal.pmed.1000233.t002
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whom 32 (63%) later achieved viral load suppression to ,400
copies/ml. This included 21 (88%) of 24 unexposed women and
11 (41%) of 27 NVP-exposed women (p,0.001; Fisher’s exact
test). Of the 692 women whose viral load was suppressed at 24 wk,
673 completed 48 wk on NNRTI-based therapy, of whom 41 (6%)
were no longer suppressed at 48 wk. This included 18 (4%) of 409
unexposed women and 23 (9%) of 264 NVP-exposed women
(p=0.02; Fisher’s exact test).
In the on-treatment analysis, which was limited to women who
completed 48 wk of follow-up on NNRTI-based ART or who were
changed to a second-line regimen in response to virologic failure at
24 wk, 38 (8%) of 450 unexposed women met criteria for failure,
compared to 33 (31%) of 107 women exposed to NVP #6m o
before starting ART (adjusted OR 5.40; 95% CI 2.94–9.92), 5
(10%) of 51 women exposed 7–12 mo prior (adjusted OR 1.02;
95% CI 0.37–2.82), and 20 (13%) of 152 women exposed .12 mo
prior (adjusted OR 1.97; 95% CI 1.05–3.68) (Table 4).
Prior Receipt of Single-Dose NVP in Multiple Pregnancies
Fourteen women (13 Zambian, one Kenyan) received single-
dose NVP during more than one pregnancy. Among these women,
the median time between the first and the more recent NVP
exposure was 1,061 days (IQR 742–1,297). Virologic failure was
found in five (50%) of ten women who completed 48 wk in the
study, including four (57%) of seven whose most recent exposure
was #6 mo before starting ART, 0 (0%) of one exposed 7–12
months prior, and one (50%) of two exposed .12 mo prior.
CD4
+ Cell Count Response
The median CD4
+ count among all participants at baseline was
148 cells/ml (IQR 77–215; n=878), at 24 wk was 282 cells/ml
(IQR 191–371; n=786), and at 48 wk was 294 cells/ml (IQR
206–404; n=762). The median CD4
+ cell count change from
baseline to 24 wk was 123 cells/ml (IQR, 57–207), and from
baseline to 48 wk was 149 cells/ml (IQR 75–232). CD4
+ response
did not differ significantly among women in the four exposure
interval strata (unpublished data).
Discussion
In this large, multi-country, prospective study, women with
prior exposure to a single, intrapartum dose of NVP were more
likely to meet the study’s primary criteria for treatment failure than
were women who were not exposed. The overall treatment failure
rate at 48 wk—which we defined conservatively to include not
only detectable viral load but also death, loss to follow-up, and
regimen changes for any reason—was 28% in this cohort, and was
Figure 1. Interval between exposure to single-dose nevirapine and starting NNRTI-based antiretroviral therapy in the NNRTI
Response Study—Zambia, Kenya, Thailand (2005 – 2008).
doi:10.1371/journal.pmed.1000233.g001
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factors in addition to prior NVP exposure, including country of
enrollment. The increased risk of treatment failure in our study
appears to be concentrated in women in whom a short period of
time had elapsed between NVP exposure and starting ART. NVP-
exposed women in whom this interval was more than 12 mo had
essentially the same prevalence of failure at 48 wk as women
without prior exposure.
When the definition of treatment failure was narrowed to
include only virologic outcomes (the ‘‘on treatment’’ analysis), we
observed a similarly increased risk of virologic failure among
women with shorter intervals between NVP exposure and starting
NNRTI-based ART. In fact, by this secondary definition, the risk
of failure was statistically evident even in those women starting
NNRTI-based ART in our pre-defined category of 12 mo or more
after exposure. It should be noted, however, that locally weighted
regression analysis indicates a clear dose-response relationship
between exposure interval and virologic failure, and that the
increased risk of failure by either our primary or on-treatment
failure definition is largely absent by 15 mo.
In 2004, Lallemant and colleagues reported on clinical
outcomes of 269 Thai women who initiated NNRTI-based ART
Figure 2. Study Schema for the NNRTI Response Study—Zambia, Kenya, Thailand (2005–2008). Among the 779 women who completed
24 wk follow-up on NNRTI-based ART (excluding the three women who were temporarily off therapy), self-reported adherence over the five visits by
week 24 was greater than 95% for 440 (95%) of 461 NVP-unexposed women and 300 (94%) of 318 NVP-exposed women (p=0.5). Among the 724
women who completed 48 weeks on NNRTI-based ART, self-reported adherence over the two visits at weeks 36 and 48 was greater than 95% for 419
(97%) of 433 NVP-unexposed women and 280 (96%) of 291 NVP-exposed women (p=0.7). f/u, follow-up; LTFU, lost to follow-up.
doi:10.1371/journal.pmed.1000233.g002
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where use of single-dose NVP was randomized [15]. At 6 mo after
ART initiation, 96 (51%) of 188 NVP-exposed women had .50
virus copies/ml plasma compared to 13 (32%) of 41 women
without prior exposure (p=0.03). In their study, the median time
between delivery and ART initiation was short (6.1 mo), and the
authors did not report comparisons of failure rates based upon
interval between NVP exposure and starting ART. In a follow-up
report presented in abstract form, the women were followed
through 18 mo and no additional failures were observed in either
group [23]. Thus, failure attributable to NVP exposure in their
study appeared to manifest within the first 6 mo of therapy.
Working in Botswana, Lockman and colleagues in 2007 were the
first to report that timing between NVP exposure and ART
initiation might be an important predictor of subsequent virologic
failure [17]. Like the Thai trial [15], participants in the Botswana
study were randomized to single-dose NVP or placebo when they
presented in labor. While NVP exposure was associated with
increased risk of virologic failure at 6 mo (8.4% versus 5.0%;
p=0.002), this risk was mainly attributable to recent exposure,
defined as occurring within 6 mo of ART initiation. NVP-exposed
women with greater exposure intervals appeared to have no
additional risk of failure. This finding is consistent with observa-
tional studies in Zimbabwe [24], Co ˆte d’Ivoire [25], Zambia
[26,27], and South Africa [28].
In this study, we also noted that the small group of women not
virologically suppressed to ,400 copies/ml at 24 wk, but who
eventually achieved suppression at 48 wk with continued NNRTI-
based therapy, contained a significantly greater proportion of
women without prior single-dose NVP compared with those who
did not achieve suppression by 48 wk. Although we cannot fully
assess whether this finding might have resulted from differences
in care between these two groups, it suggests that women with
prior NVP exposure who do not achieve virologic suppression at
24 wk have a greater likelihood of remaining unsuppressed at
48 wk. This observation raises the possibility that clinicians
should consider switching to second-line therapy for NVP-exposed
women who do not achieve viral load suppression at 24 wk on
NNRTI-based therapy.
Strengths of our study include its large cohort size, good follow-
up rates, high reported adherence to treatment with correspond-
ingly high virologic suppression, and inclusion of women with both
short and long intervals between exposure to intrapartum NVP
and starting ART. These characteristics of the study allowed a
fairly nuanced analysis of the relationship between the exposure
interval and risk of future virologic failure (Figure 3). In addition,
the study’s multi-country population and differing approaches to
clinical HIV management support the external validity of our
conclusions. The primary limitation of our study is that the
exposure of interest—use of intrapartum NVP—was not random-
ized, leaving open the possibility that exposed and unexposed
women may differ in some systematic way other than their single-
dose NVP use. During the protocol planning process, we noted
that NVP-unexposed women seeking care tended to have more
advanced HIV disease than did exposed women. Even among
women of similar CD4
+ status, NVP-unexposed women had
generally more advanced disease by WHO staging than did NVP-
exposed women. Thus, we elected to group-match our enrollees
on both CD4
+ and WHO disease stage to mitigate this potential
confounding. We decided not to use ultrasensitive viral load testing
for patient management nor to categorize failure in our analysis
for two reasons. First, the more sensitive viral load assay was not
available at the African sites and would have required expatriation
of study specimens, a practice that is increasingly discouraged by
local authorities. Second, the less sensitive assay is the current
standard for clinical practice in both African sites. We thus
believed that use of a 400 copies/ml threshold would yield
outcomes that reflected the realities of local clinical practice.
Third, we followed women for 48 wk, and longer-term virologic
response rates were not assessed. Finally, our results may not
apply to women who receive a prophylactic ‘‘tail’’ of other drugs,
such as ZDV/3TC [29] or single-dose tenofovir/emtricitabine
[30] in order to reduce the emergence of single-dose NVP-related
resistance.
Figure 3. Time between exposure to single-dose NVP and starting antiretroviral therapy and the probability of treatment failure in
the NNRTI Response Study—Zambia, Kenya, Thailand (2005–2008). Locally weighted regression (LOESS) models of the risk of treatment
failure as a function of the time interval between NVP ingestion and starting ART. The left panel defines treatment failure according to the study’s
primary definition; the right panel defines treatment failure according to a planned secondary definition (see Methods). The horizontal dotted line
indicates the failure rate among the women who were not exposed to single-dose NVP. The individual plusses (+) indicated on each panel represent
individual patients who were either failing (top) or not failing (bottom).
doi:10.1371/journal.pmed.1000233.g003
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primary analysis in the NNRTI Response Study—Zambia,
Kenya, Thailand (2005–2008).
Factors
No.
Failures/N
(%)
Unadjusted ORs
(95% Exact
Confidence
Limits)
Adjusted ORs
a
(95% Wald
Confidence
Limits)
Interval between single-
dose nevirapine exposure
and starting NNRTI-based
ART, mo
Unexposed 132/523 (25) Ref Ref
1-6 47/116 (41) 2.02 (1.29, 3.13) 2.16 (1.34, 3.49)
7–12 25/67 (37) 1.76 (0.99, 3.09) 1.47 (0.82, 2.65)
.12 42/172 (24) 0.96 (0.63, 1.45) 1.02 (0.66, 1.59)
Country
Thailand 34/217 (16) Ref Ref
Zambia 159/509 (31) 2.44 (1.60, 3.81) 2.60 (1.63, 4.14)
Kenya 53/152 (35) 2.87 (1.71, 4.89) 2.17 (1.23, 3.82)
CD4
+ lymphocyte count
(cells/ml)
$200 58/255 (23) Ref Ref
50 to 199 126/479 (26) 1.21 (0.84, 1.77) 1.21 (0.81, 1.81)
0 to 49 62/144 (43) 2.56 (1.61, 4.09) 2.60 (1.56, 4.33)
Plasma viral load, log
copies/ml (missing=6)
,4.0 20/114 (17) Ref Ref
4.0 to ,5.0 75/296 (25) 1.59 (0.90, 2.92) 1.72 (0.96, 3.08)
$5.0 149/462 (32) 2.24 (1.31, 3.98) 2.01 (1.14, 3.55)
WHO stage
I or II 88/416 (21) Ref Ref
III 121/358 (34) 1.90 (1.36, 2.66) 1.47 (1.01, 2.13)
IV 37/104 (36) 2.06 (1.25, 3.35) 1.55 (0.91, 2.65)
Age (y)
$30 130/560 (23) Ref Ref
,30 116/318 (36) 1.90 (1.39, 2.60) 1.81 (1.29, 2.54)
Hemoglobin, g/dl;
(missing=16)
$8.0 215/808 (27) Ref Ref
,8.0 27/54 (50) 2.75 (1.52, 5.00) 1.94 (1.06, 3.55)
Body mass index, kg/m
2
$18 161/678 (24) Ref Ref
,18 85/200 (42) 2.37 (1.68, 3.35) 1.66 (1.15, 2.39)
Weight, kg
$50 123/533 (23) Ref —
,50 123/345 (36) 1.85 (1.35, 2.52) —
NNRTI initially prescribed
NVP 231/820 (28) Ref —
EFV 15/58 (26) 0.89 (0.45, 1.67) —
TB at baseline
No active TB 221/807 (27) Ref —
Active TB 25/71 (35) 1.44 (0.83, 2.46) —
See Methods for definition of primary analysis.
aAdjusted ORs controlling for country, CD4 cell count, viral load, WHO stage,
age, hemoglobin, and body mass index (all as categorical variables as in
Table 1. Twenty-one observations are not included, owing to missing baseline
results for either viral load or hemoglobin.
Ref, referent group.
doi:10.1371/journal.pmed.1000233.t003
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ART after One Intrapartum Dose of Nevirapine
PLoS Medicine | www.plosmedicine.org 9 February 2010 | Volume 7 | Issue 2 | e1000233Ever since the HIVNET 012 trial demonstrated its prophylactic
efficacy [3], intrapartum NVP has been a nexus of controversy
[31–33]. Perhaps the strongest opposition to single-dose NVP
surrounds its potential to induce viral resistance and thereby
adversely affect a mother’s future treatment options. Fortunately,
this report, along with others [5,17,24–27], provides some
reassurance (Table 5). It is now evident that the risk of intrapartum
NVP compromising a mother’s future response to an NNRTI-
containing regimen is confined mostly to women in whom ART
will be needed within 12–15 mo of delivery. Where CD4
+ testing
is routinely available, programs could minimize the number of
women who fall into this risk group by increasing the CD4
+
threshold for starting ART in pregnancy to 350 cells/ml, as
recommended in the 2006 WHO guidelines [29]. The benefit of
this approach would be 2-fold. First, it would ensure that most
women exposed to single-dose NVP would not need therapy for at
Table 5. Studies of virologic response rates to NNRTI-based treatment among women previously exposed to single-dose NVP.
Study Site
[Reference]
Follow-Up
Reported in
This Table
a
Viral Load
Threshold for
Treatment
Response,
Copies/ml PMTCT Regimen
b Exposure Interval n
c
Proportion
Responding to
Treatment
d
p-Value
(versus SDNVP
Unexposed)
Thailand [16] 6 mo ,50 ZDV — 41 68%
ZDV + SDNVP Median 6 mo
since exposure
188 49% 0.03
Botswana [17] 12 mo ,400 ZDV ,6m o
since delivery
36 97%
ZDV + SDNVP ,6m o
since exposure
24 54% ,0.001
ZDV $6m o
since delivery
70 86%
ZDV + SDNVP $6m o
since exposure
88 88% 0.76
Zimbabwe [24] 12 mo ,400 ZDV 32 72%
SDNVP Median 17 mo
since exposure
20 65% 0.60
Zambia [26] 6 mo ,400 Unexposed 0
SDNVP ,6m o
since exposure
8 38% —
SDNVP 6–12 mo
since exposure
22 59% —
SDNVP 12–24 mo
since exposure
61 72% —
SDNVP .24 mo
since exposure
70 77% —
Cote d’Ivoire [27] 12 mo ,500 Unexposed 97 85%
SDNVP 6 ZDV or ZDV/3TC
e Median 21 mo
since exposure
122 78% 0.23
South Africa [28] 6 mo ,50 Unexposed 60 91%
SDNVP 18–36 mo
since exposure
94 98% 0.21
Zambia, Kenya,
Thailand [this study]
12 mo ,400 Unexposed 450 92% —
SDNVP 6 ZDV
f ,6m o
since exposure
107 69% ,0.01
SDNVP 6 ZDV
f 7–12 mo
since exposure
51 90% 0.79
SDNVP 6 ZDV
f .12 mo
since exposure
152 87% 0.11
aSome studies report outcomes at additional time points that are not listed here.
bWomen who received ZDV or ZDV/3TC typically received the regimen from ,36 wk gestation.
cNumbers of patients includes those from whom a virologic response was available in the report.
dProportions estimated by Kaplan-Meier method for references [17] and [28]. All others are raw proportions.
eWomen who received NVP for PMTCT in this study got SDNVP alone, ZDV + SDNVP, or ZDV/3TC + SDNVP. Response rates listed here are from Table 3 in reference [27].
p-Value calculated using Fisher’s exact test.
fAll women in Thailand who were exposed to SDNVP also received antenatal ZDV; in Zambia and Kenya antenatal ZDV was not used. p-Values calculated using Fisher’s
exact test for each exposure interval compared to SDNVP unexposed.
SDNVP, single dose intrapartum nevirapine.
doi:10.1371/journal.pmed.1000233.t005
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PLoS Medicine | www.plosmedicine.org 10 February 2010 | Volume 7 | Issue 2 | e1000233least a year. Second, through the provision of suppressive therapy
to precisely those women at highest transmission risk, it would
prevent more perinatal HIV infections [29]. In the occasional
circumstance where a woman did need therapy soon after single-
dose NVP exposure, a protease inhibitor-containing regimen or a
triple nucleoside regimen could be prescribed [34].
Worldwide, approximately one-third of HIV-exposed infants
receive perinatal HIV prophylaxis in any form [35]. Single-dose
intrapartum and neonatal NVP is among the simplest and most
feasible interventions available and remains a cornerstone of
perinatal HIV prevention in many under-resourced settings. This
study indicates that, when used judiciously in conjunction with
ART for women eligible for treatment, single-dose NVP to
prevent mother-to-child HIV transmission can be administered
without substantially comprising the mother’s future antiretroviral
treatment options.
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Background. Every year, acquired immunodeficiency
syndrome (AIDS) kills nearly 300,000 children. At the end of
2008, 2.1 million children were positive for the human
immunodeficiency virus (HIV), the cause of AIDS, and in that
year alone more than 400,000 children were newly infected
with HIV. Most HIV-positive children acquire the virus from
their mothers during pregnancy or birth or through
breastfeeding, so-called mother-to-child transmission
(MTCT). Without intervention, 15%–30% of babies born to
HIV-positive women become infected with HIV during
pregnancy and delivery, and a further 5%–20% become
infected through breastfeeding. These rates of infection can
be greatly reduced by treating the mother and her newborn
baby with antiretroviral drugs. A single dose of nevirapine (a
‘‘non-nucleoside reverse transcriptase inhibitor’’ or NNRTI)
given to the mother at the start of labor and to the baby soon
after birth reduces the risk of MTCT by nearly a half; a further
reduction in risk can be achieved by giving the mother and
her baby additional antiretroviral drugs during pregnancy,
around the time of birth, and while breast-feeding.
Why Was This Study Done? Single-dose nevirapine is the
mainstay of MTCT prevention programs in many poor
countries but can induce resistance to nevirapine and to
other NNRTIs. The drugs used to treat HIV infections fall into
several different classes defined by how they stop viral
growth. HIV can become resistant to any of these drugs and
a virus strain that is resistant to one member of a drug class
is often also resistant to other members of the same class.
Because most first-line antiretroviral therapies (ARTs;
cocktails of antiretroviral drugs) used in developing
countries contain an NNRTI and because HIV-positive
mothers eventually need ART to safeguard their own
health, the resistance to NNRTIs that is induced in women
by single-dose nevirapine might decrease the chances that
ART will work for them later. In this multi-country,
prospective cohort study, the researchers compare the
effectiveness of NNRTI-containing ART in a group (cohort)
of women previously exposed to single-dose nevirapine
during childbirth to its effectiveness in a group of unexposed
women. They also investigate whether the length of time
between nevirapine exposure and ART initiation affects ART
effectiveness.
What Did the Researchers Do and Find? The researchers
enrolled 355 HIV-positive nevirapine-exposed women and
523 HIV-positive nevirapine-unexposed women in Zambia,
Kenya, and Thailand who were just starting NNRTI-
containing ART and followed them for 48 weeks. They
defined ART failure as death, discontinuation of NNRTI-
containing ART, or a high virus load in the blood (virologic
failure) at 24 or 48 weeks. ART failed in nearly a third of the
nevirapine-exposed women but in only a quarter of the
nevirapine-unexposed women. Women who began ART
within 6 months of taking single-dose nevirapine to
prevent MTCT were twice as likely to experience ART
failure as women not exposed to single-dose nevirapine.
Women who began ART 7–12 months after single-dose
nevirapine had a slightly increased risk of ART failure
compared to unexposed women but this increased risk
was not statistically significant; that is, it could have occurred
by chance. Women who began ART more than 12 months
after single-dose nevirapine did not have an increased risk of
ART failure compared to unexposed women. Finally, the
researchers used a statistical method called locally weighted
regression analysis to confirm that an increase in the interval
between single-dose nevirapine and ART initiation decreased
the risk of virologic failure.
What Do These Findings Mean? These findings, which
confirm and extend the results of previous studies and which
are likely to be generalizable to other resource-poor
countries, indicate that single-dose nevirapine given to
women to prevent MTCT increases their risk of subsequent
ART failure. More positively, they also show that this
increased failure risk is largely confined to women who
begin ART within a year of exposure to nevirapine. Because
of the study design, it is possible that the nevirapine-
exposed women share some additional, undefined
characteristic that makes them more likely to fail ART than
unexposed women. Even so, these findings suggest that,
provided NNRTI-containing ART is not given to HIV-positive
women within a year of nevirapine exposure, single-dose
nevirapine can be safely used to prevent MTCT without
compromising the mother’s future antiretroviral treatment
options.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000233.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS,
on treatments for HIV/AIDS, and on HIV infection in infants
and children
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on children, HIV, and AIDS and on preventing mother-
to-child transmission of HIV (in English and Spanish)
N UNICEF also has information about children and HIV and
AIDS (in several languages)
N The World Health Organization has information on mother-
to-child transmission of HIV
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